A detailed history of Health Cor Management, L.P. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Health Cor Management, L.P. holds 70,000 shares of SNDX stock, worth $1.52 Million. This represents 1.68% of its overall portfolio holdings.

Number of Shares
70,000
Previous 859,240 91.85%
Holding current value
$1.52 Million
Previous $20.6 Million 91.37%
% of portfolio
1.68%
Previous 2.58%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$20.64 - $26.24 $16.3 Million - $20.7 Million
-789,240 Reduced 91.85%
70,000 $1.78 Million
Q3 2022

Nov 14, 2022

SELL
$18.51 - $24.79 $1.19 Million - $1.59 Million
-64,160 Reduced 6.95%
859,240 $20.6 Million
Q2 2022

Aug 15, 2022

SELL
$13.64 - $19.48 $3.51 Million - $5.01 Million
-257,100 Reduced 21.78%
923,400 $17.8 Million
Q1 2022

May 16, 2022

BUY
$14.84 - $22.15 $340,429 - $508,120
22,940 Added 1.98%
1,180,500 $20.5 Million
Q4 2021

Feb 14, 2022

SELL
$15.23 - $22.47 $869,785 - $1.28 Million
-57,110 Reduced 4.7%
1,157,560 $25.3 Million
Q3 2021

Nov 15, 2021

SELL
$13.87 - $19.8 $7.44 Million - $10.6 Million
-536,672 Reduced 30.64%
1,214,670 $23.2 Million
Q2 2021

Aug 16, 2021

BUY
$13.42 - $25.18 $5.1 Million - $9.56 Million
379,862 Added 27.7%
1,751,342 $30.1 Million
Q1 2021

May 17, 2021

BUY
$19.28 - $24.59 $5.8 Million - $7.4 Million
300,930 Added 28.11%
1,371,480 $30.7 Million
Q4 2020

Feb 16, 2021

BUY
$15.1 - $26.44 $15.7 Million - $27.5 Million
1,038,350 Added 3224.69%
1,070,550 $23.8 Million
Q3 2020

Nov 16, 2020

BUY
$13.39 - $17.48 $431,158 - $562,856
32,200 New
32,200 $475,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $1.23B
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Health Cor Management, L.P. Portfolio

Follow Health Cor Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Health Cor Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Health Cor Management, L.P. with notifications on news.